Please login to the form below

Not currently logged in

Bad news for Portola as CHMP considers Factor Xa drugs

The committee are ‘unlikely’ to adopt a positive opinion for betrixaban

NICE reverses its rejection of Eisai’s Lenvima

EISAIThe cost-effectiveness watchdog has now backed the thyroid cancer treatment

MHRA suspends new prescriptions of fibroid drug Esmya

Gedeon Richter buildingThe delay to Gedeon Richter's therapy follows reports of serious liver damage in some patients

AZ bags key lung cancer approval for Imfinzi

AstraZeneca AZBecomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Pfizer files third-gen ALK inhibitor for lung cancer

The US FDA is set to make a decision on lorlatinib later this year

NICE backs Roche’s Gazyvaro after initial rejection

Roche Basel SwitzerlandAn undisclosed discount swayed the cost-effectiveness body

NICE backs EUSA's RCC treatment Fotivda

EUSA PharmaThe UK’s cost-effectiveness watchdog recommends its first-line use

FDA hands GSK a reprieve by blocking Novartis generic

GSK - logo on buildingThe Advair rival could be delayed until 2019

KeysMoving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...